L 754394 | CAS#160729-91-9 | HIV-1 protease inhibitor

MedKoo Cat#: 596689 | Name: L 754394

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 754394 is a potent and specific inhibitor of the HIV-1 protease.

Chemical Structure

L 754394

CAS#160729-91-9

Theoretical Analysis

MedKoo Cat#: 596689

Name: L 754394

CAS#: 160729-91-9

Chemical Formula: C38H47N5O5

Exact Mass: 653.3577

Molecular Weight: 653.82

Elemental Analysis: C, 69.81; H, 7.25; N, 10.71; O, 12.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L 754394; L-754394; L754394; L-754,394; L 754,394; L754,394;

IUPAC/Chemical Name

(S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(furo[2,3-b]pyridin-5-ylmethyl)piperazine-2-carboxamide

InChi Key

UBUFVRJUGFJQSI-PPJSLLJVSA-N

InChi Code

InChI=1S/C38H47N5O5/c1-38(2,3)41-36(47)32-24-42(22-26-18-28-13-16-48-37(28)39-21-26)14-15-43(32)23-30(44)19-29(17-25-9-5-4-6-10-25)35(46)40-34-31-12-8-7-11-27(31)20-33(34)45/h4-13,16,18,21,29-30,32-34,44-45H,14-15,17,19-20,22-24H2,1-3H3,(H,40,46)(H,41,47)/t29-,30+,32+,33-,34+/m1/s1

SMILES Code

O=C(N[C@@H]1[C@H](O)CC2=C1C=CC=C2)[C@H](CC3=CC=CC=C3)C[C@H](O)CN4[C@H](C(NC(C)(C)C)=O)CN(CC5=CN=C(OC=C6)C6=C5)CC4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 653.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, Chauret N, Ouellet M, Nicoll-Griffith DA. Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol. 2004 Oct;17(10):1356-61. PubMed PMID: 15487896. 2: Achira M, Suzuki H, Ito K, Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci. 1999;1(4):E18. PubMed PMID: 11741214; PubMed Central PMCID: PMC2751348. 3: Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. PubMed PMID: 10997946. 4: Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry. 2000 Apr 18;39(15):4276-87. PubMed PMID: 10757976. 5: Lin JH, Chen IW, Chiba M, Nishime JA, Deluna FA. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation. Drug Metab Dispos. 2000 Apr;28(4):460-6. PubMed PMID: 10725315. 6: Nishime JA, Wang RW, Lin JH, Chiba M. Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor. Drug Metab Dispos. 1999 Sep;27(9):972-6. PubMed PMID: 10460793. 7: Sahali-Sahly Y, Balani SK, Lin JH, Baillie TA. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem Res Toxicol. 1996 Sep;9(6):1007-12. PubMed PMID: 8870989. 8: Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther. 1995 Dec;275(3):1527-34. PubMed PMID: 8531125. 9: Lin JH, Chiba M, Chen IW, Vastag KJ, Nishime JA, Dorsey BD, Michelson SR, McDaniel SL. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther. 1995 Jul;274(1):264-9. PubMed PMID: 7616407.